Kalorama Information: Qiagen Could Bolster Clinical NGS Presence with GeneReader System
NEW YORK, Nov. 10, 2015 /PRNewswire/ -- The GeneReader research and clinical NGS solution will expand Qiagen's market opportunity in NGS markets with product sales from sample preparation through automated interpretation of clinical sequencing results, according to Kalorama Information. Currently, the healthcare market researcher ranks Qiagen behind Illumina, Agilent, Thermo Fisher and Fluidigm in market share for NGS library prep and target enrichment according to its report Library Preparation and Target Enrichment for Next Generation Sequencing Product Markets. Likewise, Qiagen has held a relative secondary market share in the overall sequencing market. However, Qiagen's position in NGS markets is set to rise substantially, particularly as it more thoroughly addresses the market for sequencing assays in clinical oncology – a market space expected by Kalorama Information to grow at a substantially higher annual rate than the overall cancer diagnostics market through 2019.
"With the launch of its GeneReader system, Qiagen will be able to touch all the bases in NGS," said Emil Salazar, Kalorama IVD and biotechnology analyst in a recent blog post.
Several years of technology acquisition and internal development have culminated for Qiagen with the launch of its comprehensive next-generation sequencing (NGS) workflow. Qiagen is already highly visible within the molecular cancer diagnostics market through its FDA-approved therascreen Rotor-Gene Q (RGQ) PCR kits for EGFR and KRAS variant testing as well as its CE-marked and internationally available PCR and pyrosequencing assays for various oncogene variants. In next-generation sequencing, Qiagen has proceeded arguably in a reverse manner to its competitors. The company has been a leader in sample preparation, including nucleic acid extraction and purification, for years. Acquisitions of CLC bio and Ingenuity systems expanded Qiagen's presence in bioinformatics at the output end of sequencing workflows. The build-out of Qiagen's NGS product portfolio was preceded by the acquisition of Biotage's Pyromark instrument family in 2008 – a distant event in the accelerated timeline of NGS innovation. Other many leading NGS players such as Illumina developed with a sequencer instrument at their center.
Complementing the unveiled GeneReader instrument, Qiagen offers open-platform sample solutions for tissue (GeneRead DNA FFPE Kit); single cells (REPLI-g WTA Single Cell Kits; potential application with CTCs); and exosomes (developed with Exosome Diagnostics). DNASeq v2.0 panels perform PCR-based target enrichment of oncogenes for sequencing on any platform. Qiagen's QiaCube performs automated extraction and library preparation; library amplification is additionally performed on the GeneRead QiaCube.
Additional market insights, including market segmentation by product, region and competitor share, are available with Kalorama Information market research reports The World Market for Cancer Diagnostics, 6th Edition; and Next Generation Sequencing Markets.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kalorama-information-qiagen-could-bolster-clinical-ngs-presence-with-genereader-system-300175237.html
SOURCE Kalorama Information